Study Summary
This trial looks at letrozole as a treatment for operable hormone receptor positive, HER2 negative breast cancer. Letrozole is an aromatase inhibitor, which works by decreasing the amount of estrogen produced by the body.
- Breast Cancer
Treatment Effectiveness
Study Objectives
1 Primary · 2 Secondary · Reporting Duration: Up to 8 weeks
Trial Safety
Safety Progress
Side Effects for
Trial Design
1 Treatment Group
Treatment (letrozole)
1 of 1
Experimental Treatment
50 Total Participants · 1 Treatment Group
Primary Treatment: Letrozole · No Placebo Group · Phase 2
Trial Logistics
Trial Timeline
Who is running the clinical trial?
Eligibility Criteria
Age 18+ · Female Participants · 7 Total Inclusion Criteria
Mark “Yes” if the following statements are true for you:Frequently Asked Questions
How many individuals are being recruited for this research endeavor?
"Affirmative. According to clinicaltrials.gov, this medical trial has resumed recruitment efforts since its initial posting on July 21st 2022 and most recent update on August 3rd 2022. The research is seeking 50 participants at a single site for enrollment." - Anonymous Online Contributor
Is enrollment for this trial still available to those seeking treatment?
"Affirmative. Clinicaltrials.gov attests to this medical study's current recruitment status, which was initially made available on July 21st 2022 and was most recently revised on August 3rd of the same year. The trial is looking for 50 participants from 1 site." - Anonymous Online Contributor
Has Letrozole been sanctioned by the Federal Drug Administration?
"As this is a Phase 2 study, there are limited data points available on the safety of Letrozole. Consequently, our team at Power has assessed it with an intermediate score of two." - Anonymous Online Contributor